Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.53 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.50 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 6/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.45 |
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | HTT | P42858 | 2/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.45 |
| ▸ | GAA | P10253 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | RECQL | P46063 | 1/20 | 0.45 |
| ▸ | MGLL | Q99685 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.44 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL94509 | 1.00 | SMN1; SMN2 (0.53) | SMN1; SMN2NOTUMSIGMAR1MEN1KMT2A | |
| SCHEMBL27570415 | 0.98 | SMN1; SMN2 (0.51) | SMN1; SMN2NOTUMSIGMAR1MEN1KMT2A | |
| SCHEMBL16340761 | 0.94 | SMN1; SMN2 (0.47) | SMN1; SMN2NOTUMSIGMAR1MEN1KMT2A | |
| SCHEMBL223608 | 0.88 | MEN1 (0.54) | SMN1; SMN2NOTUMSIGMAR1MEN1KMT2A | |
| SCHEMBL9217182 | 0.81 | SMN1; SMN2 (0.49) | SMN1; SMN2NOTUMSIGMAR1MEN1KMT2A | |
| SCHEMBL28674863 | 0.81 | SMN1; SMN2 (0.49) | SMN1; SMN2NOTUMSIGMAR1MEN1KMT2A | |
| SCHEMBL5537868 | 0.81 | NOTUM (0.50) | SMN1; SMN2NOTUMSIGMAR1MEN1KMT2A | |
| Benzoic Acid SCHEMBL11442175 | 0.80 | ALDH1A1 (0.54) | SMN1; SMN2NOTUMMEN1KMT2ATSHR | |
| SCHEMBL25774868 | 0.77 | HSD17B3 (0.51) | SMN1; SMN2MEN1KMT2AALDH1A1MAPT | |
| SCHEMBL5250971 | 0.77 | CYP2A6 (0.47) | SIGMAR1KMT2AALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025042896-A1 | DNA TOPOISOMERASE IIβ INHIBITORS | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2025-02-27 | — | — | WO | disclosed |
| CN-115348959-B | Heteroaryl compounds and their therapeutic use in conditions associated with altered beta-glucocerebrosidase activity | GT增益治疗股份有限公司 | 2025-01-07 | — | — | CN | disclosed |
| CN-118785904-A | Conjugates of TASK1/3 channel blockers and P2X3 receptor antagonists for the treatment of sleep apnea | 拜耳公司 | 2024-10-15 | — | — | CN | disclosed |
| CN-118541153-A | Conjugates of a TASK1/3 channel blocker and a norepinephrine reuptake inhibitor for the treatment of sleep apnea | 拜耳公司 | 2024-08-23 | — | — | CN | disclosed |
| CN-118434415-A | Conjugates of TASK1/3 channel blockers and muscarinic receptor antagonists for the treatment of sleep apnea | 拜耳公司 | 2024-08-02 | — | — | CN | disclosed |
| CN-116057057-A | Conjugates of alpha 2-adrenoceptor subtype C (alpha-2C) antagonists and TASK1/3 channel blockers for the treatment of sleep apnea | 拜耳公司 | 2023-05-02 | — | — | CN | disclosed |
| CN-115697418-A | Compositions and methods for treating muscular dystrophy | 艾维迪提生物科学公司 | 2023-02-03 | — | — | CN | disclosed |
| CN-115666589-A | Compositions and methods for treating facioscapulohumeral muscular dystrophy | 艾维迪提生物科学公司 | 2023-01-31 | — | — | CN | disclosed |
| CN-115348959-A | Heteroaryl compounds and their therapeutic use in disorders associated with altered beta-glucocerebrosidase activity | 增益治疗股份有限公司 | 2022-11-15 | — | — | CN | disclosed |
| US-20220218700-A1 | COMBINATION OF AN ?2-ADRENOCEPTOR SUBTYPE C (ALPHA-2C) ANTAGONISTS WITH A TASK1/3 CHANNEL BLOCKER FOR THE TREATMENT OF SLEEP APNEA | BAYER AKTIENGESELLSCHAFT (DE) | 2022-07-14 | — | — | US | disclosed |
| CN-114375296-A | Nucleic acid polypeptide compositions and uses thereof | 艾维迪提生物科学公司 | 2022-04-19 | — | — | CN | disclosed |
| CN-114375297-A | UNA imides and uses thereof | 艾维迪提生物科学公司 | 2022-04-19 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220218700-A1 | COMBINATION OF AN ?2-ADRENOCEPTOR SUBTYPE C (ALPHA-2C) ANTAGONISTS WITH A TASK1/3 CHANNEL BLOCKER FOR THE TREATMENT OF SLEEP APNEA | ADRA2C, ADRB2, ADRA1D | SMN1; SMN2 2108/4885NOTUM 3650/4885SIGMAR1 127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.